Fulcrum Therapeutics Q1 2026 Earnings Narrowing Losses as Pipeline Advances GRAL Q1 2026 Earnings EPS Beat Driven by Cost Control Amidst Uncertain Revenue Trajectory Ashland Inc ASH Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions Arcturus Therapeutics Holdings Inc ARCT Q1 2026 Earnings Narrower Net Loss Beats Estimates Amid Pipeline Progress TONX Q1 2026 Earnings Significant EPS Beat Drives 458 Stock Gain